Insider Buying: Prelude Therapeutics (NASDAQ:PRLD) Director Acquires 2,815,315 Shares of Stock
Prelude Therapeutics Incorporated (NASDAQ:PRLD – Get Free Report) Director Orbimed Advisors Llc bought 2,815,315 shares of Prelude Therapeutics stock in a transaction that occurred on Tuesday, April 21st. The shares were acquired at an average cost of $4.44 per share, with a total value of $12,499,998.60. Following the acquisition, the director owned 11,808,945 shares of […]
23 Apr 23:40 · The Markets Daily